UGCG and hepatocellular carcinoma: Our data indicate that, although sorafenib alters the sphingolipidic metabolism in hepatoma cells via ASMase activation, ceramide toxicity is partially reduced by the simultaneous induction of ceramide-eliminating enzymes, in particular GCS.